These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 4055808)

  • 1. Acetone-treated pertussis vaccine--a potent and safer new pertussis vaccine.
    Saran G
    J Biol Stand; 1985 Oct; 13(4):315-20. PubMed ID: 4055808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative biological activities of whole cell pertussis vaccine and a new acellular preparation.
    García-Sánz JA; Ruiz-Puente J; Jiménez-Paredes J; González-Pacheco M; Villalva-Posada H
    Vaccine; 1985 Mar; 3(1):23-6. PubMed ID: 4039870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutaraldehyde inactivated pertussis vaccine: a less histamine sensitizing vaccine.
    Gupta RK; Sharma SB; Ahuja S; Saxena SN
    J Biol Stand; 1987 Apr; 15(2):159-64. PubMed ID: 3110164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pertussis vaccines: present status.
    Christodoulides M
    Adv Biotechnol Processes; 1990; 13():169-99. PubMed ID: 2185783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative toxicity, protective, histamine sensitizing and leucocytosis promoting activities in mice of Bordetella pertussis culture fluid, bacterial cells and cell extracts.
    Megret F; Fournier JM; Alouf JE
    Med Microbiol Immunol; 1984; 173(4):225-32. PubMed ID: 6096686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of different inactivating agents on the potency, toxicity and stability of pertussis vaccine.
    Gupta RK; Sharma SB; Ahuja S; Saxena SN
    J Biol Stand; 1987 Jan; 15(1):87-98. PubMed ID: 3104344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vaccine from the cell fragments of Bordetella pertussis. I. Protective, sensitizing properties and morphological characteristics of the vaccine].
    Zakharova MS; Shirko GN; Gureeva AA; Pereverzev NA
    Zh Mikrobiol Epidemiol Immunobiol; 1976 Nov; (11):103-8. PubMed ID: 64095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a pertussis component vaccine in Japan.
    Sato Y; Kimura M; Fukumi H
    Lancet; 1984 Jan; 1(8369):122-6. PubMed ID: 6140441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Collaborative study for the standardisation of the histamine sensitizing test in mice and the CHO cell-based assay for the residual toxicity testing of acellular pertussis vaccines.
    Xing D; Maes A; Behr-Gross ME; Costanzo A; Daas A; Buchheit KH
    Pharmeur Bio Sci Notes; 2010 Apr; 2010(1):51-63. PubMed ID: 20223190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The safety and protective properties of a new cell-free pertussis vaccine in animal trials].
    Bazhanova IG; Remova TN; Ozeretskovskaia MN; Shmeleva EI; Mertsalova NU; Sukhinova EE; Chuprinina RP; Bulk VF; Semina IE; Koval'skaia SIa
    Zh Mikrobiol Epidemiol Immunobiol; 1994; (1):40-5. PubMed ID: 8184612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
    BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of vaccines against pertussis caused by Bordetella holmesii using a mouse intranasal challenge model.
    Saito M; Odanaka K; Otsuka N; Kamachi K; Watanabe M
    Microbiol Immunol; 2016 Sep; 60(9):599-608. PubMed ID: 27515393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of the stability of pertussis vaccine OCO-3 standard].
    Chuprinina RP; Alekseeva IA
    Zh Mikrobiol Epidemiol Immunobiol; 2004; (5):68-71. PubMed ID: 15554317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two different histamine-sensitizing activities of pertussis vaccine observed in mice on the 4th and 12th days of sensitization.
    Horiuchi Y; Feng DJ; Kameyama S; Takahashi M; Asada S; Asakawa S; Ishida S
    Jpn J Med Sci Biol; 1993 Feb; 46(1):17-27. PubMed ID: 8230805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between mouse intracerebral potency & 50 per cent histamine sensitizing dose of pertussis vaccine.
    Gupta RK; Sharma SB; Ahuja S; Saxena SN
    Indian J Med Res; 1989 May; 89():144-9. PubMed ID: 2476391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative characteristics of the toxic properties of the whooping cough microbes].
    Chuprinina RP
    Zh Mikrobiol Epidemiol Immunobiol; 1975 Sep; 0(9):111-6. PubMed ID: 173120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified intra-cerebral challenge assay for acellular pertussis vaccines: comparisons among whole cell and acellular vaccines.
    Gaines-Das R; Horiuchi Y; Zhang SM; Newland P; Kim Y; Corbel M; Xing D
    Vaccine; 2009 Nov; 27(49):6824-32. PubMed ID: 19765397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of a safe, potent and immunogenic partially purified acellular pertussis vaccine using simple indigenous techniques.
    Gupta RK; Saxena SN; Sharma SB; Ahuja S
    Dev Biol Stand; 1991; 73():205-22. PubMed ID: 1778314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Action of Haemophilus pertussis vaccine on resistance to anaphylaxis, histamine allergy, serotonin, acetylcholine and infection, in the murine species and the human genus. Experiences in 30 allergic children with pertussis-tetanus-diphtheria triple vaccine].
    MATHOV E
    Sem Med; 1960 Sep; 117():1085-99. PubMed ID: 13768138
    [No Abstract]   [Full Text] [Related]  

  • 20. The detoxification of Bordetella pertussis with glutaraldehyde.
    Iida T; Horiuchi Y
    J Biol Stand; 1987 Jan; 15(1):17-26. PubMed ID: 2881932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.